Hunan Jiudian Pharmaceutical Co., Ltd.

SZSE:300705 Stock Report

Market Cap: CN¥7.7b

Hunan Jiudian Pharmaceutical Balance Sheet Health

Financial Health criteria checks 6/6

Hunan Jiudian Pharmaceutical has a total shareholder equity of CN¥2.4B and total debt of CN¥367.3M, which brings its debt-to-equity ratio to 15.4%. Its total assets and total liabilities are CN¥3.2B and CN¥857.7M respectively. Hunan Jiudian Pharmaceutical's EBIT is CN¥537.7M making its interest coverage ratio 44.8. It has cash and short-term investments of CN¥710.0M.

Key information

15.4%

Debt to equity ratio

CN¥367.34m

Debt

Interest coverage ratio44.8x
CashCN¥710.04m
EquityCN¥2.38b
Total liabilitiesCN¥857.67m
Total assetsCN¥3.24b

Recent financial health updates

We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Can Stay On Top Of Its Debt

Nov 29
We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Can Stay On Top Of Its Debt

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Jun 23
Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Recent updates

Investors Don't See Light At End Of Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Tunnel And Push Stock Down 29%

Dec 31
Investors Don't See Light At End Of Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Tunnel And Push Stock Down 29%

We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Can Stay On Top Of Its Debt

Nov 29
We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Can Stay On Top Of Its Debt

Do Hunan Jiudian Pharmaceutical's (SZSE:300705) Earnings Warrant Your Attention?

Oct 22
Do Hunan Jiudian Pharmaceutical's (SZSE:300705) Earnings Warrant Your Attention?

With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

Aug 12
With Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) It Looks Like You'll Get What You Pay For

Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Jun 23
Here's Why Hunan Jiudian Pharmaceutical (SZSE:300705) Can Manage Its Debt Responsibly

Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

May 21
Hunan Jiudian Pharmaceutical (SZSE:300705) Is Increasing Its Dividend To CN¥0.321

Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Apr 12
Here's Why We Think Hunan Jiudian Pharmaceutical (SZSE:300705) Might Deserve Your Attention Today

Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Mar 04
Earnings Not Telling The Story For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705) After Shares Rise 27%

Financial Position Analysis

Short Term Liabilities: 300705's short term assets (CN¥1.6B) exceed its short term liabilities (CN¥377.7M).

Long Term Liabilities: 300705's short term assets (CN¥1.6B) exceed its long term liabilities (CN¥479.9M).

Debt to Equity History and Analysis

Debt Level: 300705 has more cash than its total debt.

Reducing Debt: 300705's debt to equity ratio has reduced from 17% to 15.4% over the past 5 years.

Debt Coverage: 300705's debt is well covered by operating cash flow (175.8%).

Interest Coverage: 300705's interest payments on its debt are well covered by EBIT (44.8x coverage).

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 15:11
End of Day Share Price 2025/01/27 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hunan Jiudian Pharmaceutical Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hao WuChasing Securities
Yizheng YangChina International Capital Corporation Limited
Yin YePing An Securities Co. Ltd.